[go: up one dir, main page]

PE20141380A1 - Imidazopiridazinas como inhibidores de quinasa akt - Google Patents

Imidazopiridazinas como inhibidores de quinasa akt

Info

Publication number
PE20141380A1
PE20141380A1 PE2013002192A PE2013002192A PE20141380A1 PE 20141380 A1 PE20141380 A1 PE 20141380A1 PE 2013002192 A PE2013002192 A PE 2013002192A PE 2013002192 A PE2013002192 A PE 2013002192A PE 20141380 A1 PE20141380 A1 PE 20141380A1
Authority
PE
Peru
Prior art keywords
compounds
halogen
cyane
hydroxy
alkyl
Prior art date
Application number
PE2013002192A
Other languages
English (en)
Inventor
Lars Barfacker
William Johnston Scott
Andrea Hagebarth
Stuart Ince
Harmut Rehwinkel
Oliver Politz
Roland Neuhaus
Hans Briem
Ulf Bomer
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of PE20141380A1 publication Critical patent/PE20141380A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE: R1 ES H, HIDROXI, HALOGENO, CIANO, C(O)(ALQUILO C1-6), ENTRE OTROS; R2 ES H, HIDROXI, HALOGENO, CIANO, NHC(O)(ALQUILO C1-6), ENTRE OTROS; R3 ES H, HIDROXI, C(O)(ALQUILO C1-6), CIANO, HALOGENO, ENTRE OTROS; R4 ES FENILO OPCIONALMENTE SUSTITUIDO UNA, DOS O TRES VECES, EN FORMA IDENTICA O DIFERENTE, CON UN ATOMO DE HALOGENO; X E Y ES CH2; n ES 0,1,2. SON COMPUESTOS PREFERIDOS: 1-[4-(6-METIL-3-FENILIMIDAZO[1,2-b]PIRIDAZIN-2-IL)FENIL]-CICLOBUTAMINA; ACIDO 2-[4-(1-AMINOCICLOBUTIL)FENIL]-3-FENILIMIDAZO[1,2-b]-PIRIDAZIN-6-CARBOXILICO; ENTRE OTROS.SE REFIERE TAMBIEN A UN PROCESO PARA PARA LA FABRICACION DE DICHOS COMPUESTOS Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DE CANCER DE MAMAS
PE2013002192A 2011-04-07 2012-04-05 Imidazopiridazinas como inhibidores de quinasa akt PE20141380A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161472732P 2011-04-07 2011-04-07

Publications (1)

Publication Number Publication Date
PE20141380A1 true PE20141380A1 (es) 2014-10-18

Family

ID=45953129

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002192A PE20141380A1 (es) 2011-04-07 2012-04-05 Imidazopiridazinas como inhibidores de quinasa akt

Country Status (43)

Country Link
US (2) US9206185B2 (es)
EP (1) EP2694510B1 (es)
JP (1) JP5906303B2 (es)
KR (1) KR20140022057A (es)
CN (1) CN103596957B (es)
AP (1) AP3597A (es)
AR (1) AR087148A1 (es)
AU (1) AU2012238589B2 (es)
BR (1) BR112013025777A2 (es)
CA (1) CA2832374A1 (es)
CL (1) CL2013002878A1 (es)
CO (1) CO6862145A2 (es)
CR (1) CR20130515A (es)
CU (1) CU24263B1 (es)
CY (1) CY1117163T1 (es)
DK (1) DK2694510T3 (es)
DO (1) DOP2013000226A (es)
EA (1) EA024890B1 (es)
EC (1) ECSP13013008A (es)
ES (1) ES2558780T3 (es)
GT (1) GT201300238A (es)
HR (1) HRP20160011T1 (es)
HU (1) HUE026323T2 (es)
IL (1) IL228567A0 (es)
JO (1) JO3068B1 (es)
MA (1) MA35016B1 (es)
ME (1) ME02316B (es)
MX (1) MX336865B (es)
NI (1) NI201300105A (es)
PE (1) PE20141380A1 (es)
PH (1) PH12013502073A1 (es)
PL (1) PL2694510T3 (es)
PT (1) PT2694510E (es)
RS (1) RS54480B1 (es)
SG (1) SG193631A1 (es)
SI (1) SI2694510T1 (es)
SM (1) SMT201600001B (es)
TN (1) TN2013000400A1 (es)
TW (1) TWI535719B (es)
UA (1) UA111739C2 (es)
UY (1) UY34006A (es)
WO (1) WO2012136776A1 (es)
ZA (1) ZA201307223B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2927660T3 (es) 2008-06-16 2022-11-10 Univ Tennessee Res Found Compuestos para el tratamiento del cáncer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
JP5906303B2 (ja) * 2011-04-07 2016-04-20 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH Aktキナーゼ阻害剤としてのイミダゾピリダジン類
CA2860724A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as akt kinase inhibitors
EP2802586B1 (en) * 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted imidazopyrazines as akt kinase inhibitors
SG11201503688SA (en) * 2012-11-30 2015-06-29 Glaxosmithkline Llc Novel pharmaceutical composition
CN105163584B (zh) * 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
US20150352121A1 (en) * 2013-03-12 2015-12-10 Glaxosmithkline Llc Combination
US20160045531A1 (en) * 2013-03-14 2016-02-18 Epizyme, Inc. Combination therapy for treating cancer
CA2936024A1 (en) * 2014-01-09 2015-07-16 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
MA46888A (fr) 2016-11-28 2021-06-02 Bristol Myers Squibb Co Inhibiteurs de gsk-3
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150368A0 (en) 1999-12-23 2002-12-01 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use
ES2286114T3 (es) 2000-03-31 2007-12-01 Ortho-Mcneil Pharmaceutical, Inc. Imidazopiridina fenil-substituidos.
ATE300540T1 (de) 2000-04-27 2005-08-15 Yamanouchi Pharma Co Ltd Imidazopyridin-derivate
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1622616B1 (en) 2003-04-24 2011-06-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN1860121A (zh) 2003-07-30 2006-11-08 S.A.L.V.A.T.实验室有限公司 用于预防和治疗癌症的取代咪唑并嘧啶
DE602005026509D1 (de) 2004-04-09 2011-04-07 Merck Sharp & Dohme Hemmer der akt aktivität
US7544677B2 (en) 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
KR20070054216A (ko) 2004-08-24 2007-05-28 바스프 악티엔게젤샤프트 이온성 액체 제조의 출발 화합물로서의 용도를 위한이미다졸륨-메틸술파이트
CN101242834A (zh) 2004-12-15 2008-08-13 默克公司 Akt活性抑制剂
CN101263142A (zh) 2005-05-20 2008-09-10 阿雷生物药品公司 Raf抑制剂化合物及其使用方法
WO2006135627A2 (en) 2005-06-10 2006-12-21 Merck & Co., Inc. Inhibitors of akt activity
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
JP5451602B2 (ja) * 2007-06-08 2014-03-26 アッヴィ・インコーポレイテッド キナーゼ阻害薬としての5−ヘテロアリール置換インダゾール類
SI2188291T1 (sl) 2007-08-14 2013-01-31 Bayer Intellectual Property Gmbh Zliti biciklični pirimidini
EA201000297A1 (ru) * 2007-08-14 2010-08-30 Байер Шеринг Фарма Акциенгезельшафт Конденсированные бициклические имидазолы
JP2011507902A (ja) 2007-12-21 2011-03-10 ワイス・エルエルシー 肝臓X受容体のモジュレーターとしてのイミダゾ[1,2−b]ピリダジン化合物
WO2009148916A1 (en) 2008-06-03 2009-12-10 Merck & Co., Inc. Inhibitors of akt activity
AU2009255329A1 (en) 2008-06-03 2009-12-10 Msd K.K. Inhibitors of Akt activity
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
JP2012516847A (ja) 2009-02-02 2012-07-26 メルク・シャープ・エンド・ドーム・コーポレイション Akt活性の阻害剤
CA2752105C (en) * 2009-02-13 2017-10-31 Matthias Vennemann Fused pyrimidines
EP2406250B1 (en) 2009-03-11 2015-08-12 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
US8546376B2 (en) * 2009-09-18 2013-10-01 Almac Discovery Limited Pharmaceutical compounds
US8975265B2 (en) * 2010-07-12 2015-03-10 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrimidines and —pyridines
WO2012013713A2 (en) 2010-07-28 2012-02-02 Bayer Pharma Aktiengesellschaft Substituted imidazo[1,2-b]pyridazines
JP5906303B2 (ja) * 2011-04-07 2016-04-20 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH Aktキナーゼ阻害剤としてのイミダゾピリダジン類

Also Published As

Publication number Publication date
JO3068B1 (ar) 2017-03-15
RS54480B1 (sr) 2016-06-30
AP3597A (en) 2016-02-19
SI2694510T1 (sl) 2016-02-29
TW201245204A (en) 2012-11-16
AR087148A1 (es) 2014-02-26
ZA201307223B (en) 2014-12-23
CR20130515A (es) 2013-12-04
TN2013000400A1 (en) 2015-03-30
CN103596957A (zh) 2014-02-19
CL2013002878A1 (es) 2014-05-02
MX2013011699A (es) 2014-01-31
JP5906303B2 (ja) 2016-04-20
CU24263B1 (es) 2017-07-04
ECSP13013008A (es) 2013-12-31
UA111739C2 (uk) 2016-06-10
DOP2013000226A (es) 2013-11-15
US9604989B2 (en) 2017-03-28
US20150368250A1 (en) 2015-12-24
SG193631A1 (en) 2013-11-29
MX336865B (es) 2016-02-04
BR112013025777A2 (pt) 2016-12-20
EA024890B1 (ru) 2016-10-31
CO6862145A2 (es) 2014-02-10
MA35016B1 (fr) 2014-04-03
EA201301130A1 (ru) 2014-07-30
CN103596957B (zh) 2016-12-07
IL228567A0 (en) 2013-12-31
ES2558780T3 (es) 2016-02-08
ME02316B (me) 2016-06-20
NI201300105A (es) 2014-07-14
TWI535719B (zh) 2016-06-01
PH12013502073A1 (en) 2014-01-13
HUE026323T2 (en) 2016-05-30
AU2012238589B2 (en) 2017-02-16
CY1117163T1 (el) 2017-04-05
GT201300238A (es) 2015-04-06
AU2012238589A1 (en) 2013-11-07
PT2694510E (pt) 2016-02-08
PL2694510T3 (pl) 2016-03-31
DK2694510T3 (en) 2016-01-18
AP2013007215A0 (en) 2013-10-31
CA2832374A1 (en) 2012-10-11
UY34006A (es) 2012-10-31
US9206185B2 (en) 2015-12-08
KR20140022057A (ko) 2014-02-21
EP2694510B1 (en) 2015-10-14
US20140113901A1 (en) 2014-04-24
EP2694510A1 (en) 2014-02-12
NZ616270A (en) 2015-09-25
CU20130135A7 (es) 2014-02-28
SMT201600001B (it) 2016-02-25
HRP20160011T1 (hr) 2016-02-12
WO2012136776A1 (en) 2012-10-11
JP2014510127A (ja) 2014-04-24

Similar Documents

Publication Publication Date Title
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
UY33950A (es) Inhibidores de benzodioxano de la producciòn de leucotrieno
CR20170367A (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
PE20171338A1 (es) Compuestos y composiciones como inhibidores de quinasa raf
EA201290726A1 (ru) Новые соли для получения фармацевтических композиций
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201201343A1 (ru) Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
EA201491623A1 (ru) Замещенные пирролидин-2-карбоксамиды
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
PE20150774A1 (es) Aminoquinolinas como inhibidores de cinasa
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a

Legal Events

Date Code Title Description
FC Refusal